Perindopril for the treatment of hypertension

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 10, 2011, Pages 1633-1642

  Ghiadoni, Lorenzo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

ACE inhibitor; angiotensin II; bradykinin; cardiovascular events; hypertension; perindopril

Indexed keywords

AMLODIPINE; ATENOLOL; BENDROFLUMETHIAZIDE PLUS NADOLOL; INDAPAMIDE; PERINDOPRIL; PERINDOPRILAT; THIAZIDE DIURETIC AGENT;

ADULT; ANGIONEUROTIC EDEMA; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; BLOOD VOLUME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHARMACOGENETICS; PULSE PRESSURE; RISK REDUCTION; SINGLE DRUG DOSE; STROKE; SYSTOLIC BLOOD PRESSURE;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYPERTENSION; INDAPAMIDE; PERINDOPRIL;

EID: 79958717127     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.585460     Document Type: Article

References (69)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2002;360:1347-60 (Pubitemid 35341298)
2. Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60 (Pubitemid 35341298)
3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23 (Pubitemid 40138015)
4. Kotseva K, Wood D, De Backer G, et al. for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
5. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13 (Pubitemid 35472129)
6. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38 (Pubitemid 20113741)
7. Turnbull F; Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35 (Pubitemid 37410190)
8. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the task force for the management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87 (Pubitemid 46924065)
9. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
10. Reid IA. The renin-angiotensin system and body function. Arch Intern Med 1985;145:1475
11. Dzau VJ. Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE. Drugs 1990;39(Suppl 2):11-16 (Pubitemid 20167010)
12. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59 (Pubitemid 351522739)
13. Dahlof B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906 (Pubitemid 41265663)
14. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98 (Pubitemid 351620109)
15. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE Trial): a randomised controlled trial. Lancet 2007;370:829-40
16. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
17. Fox KM; EURopean trial On reduction of cardiac events with perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8 (Pubitemid 37093919)
18. Vincent M, Marchand B, Richmond G, et al. Synthesis and ACE inhibitory activity of the stereoisomers of perindopril (S 9490) and perindoprilate (S 9780). Drug Des Discov 1992;9:11-28
19. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20 (Pubitemid 28182680)
20. Telejko E. Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin 2007;23:953-60 (Pubitemid 46799577)
21. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54 (Pubitemid 126613653)
22. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92 (Pubitemid 28496194)
23. Vanhoutte PM. Endothelial dysfunction and inhibition of converting enzyme. Eur Heart J 1998;19(Suppl J):J7-15 (Pubitemid 28427115)
24. Comini L, Bachetti T, Cargnoni A, et al. Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharmacol Res 2007;56:42-8 (Pubitemid 46990929)
25. Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002;39(2 Pt 2):634-8 (Pubitemid 34165197)
26. Ceconi C, Francolini G, Olivares A, et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007;577:1-6 (Pubitemid 47632513)
27. Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989;7(Suppl 5):S11-16 (Pubitemid 19269331)
28. Devissaguet JP, Ammoury N, Devissaguet M, et al. Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundam Clin Pharmacol 1990;4:175-89 (Pubitemid 20137121)
29. Alfakih K, Hall AS. Perindopril. Expert Opin Pharmacother 2006;7:63-71 (Pubitemid 43056423)
30. Verpooten GA, Genissel PM, Thomas JR, et al. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. Br J Clin Pharmacol 1991;32:187-92
31. Louis WJ, Conway EL, Krum H, et al. Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril. Clin Exp Pharmacol Physiol Suppl 1992;19:55-60
32. Salvetti A. Newer ACE inhibitors. A look at the future. Drugs 1990;40:800-28 (Pubitemid 120032432)
33. Salvetti A, Di Venanzio L, Arrighi P, et al. Throuht: peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors. J Hypertens 1994;12(Suppl 8):S91-5
34. Lecocq B, Funck-Brentano C, Lecocq V, et al. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin Pharmacol Ther 1990;47:397-402 (Pubitemid 20115028)
35. Thiollet M, Funck-Brentano C, Grande JD, et al. The pharmacokinetics of perindopril in patients with liver cirrhosis. Br J Clin Pharmacol 1992;33:326-8
36. Hurst M. Jarvis B Perindopril: an updated review of its use in hypertension. Drugs 2001;61:867-96 (Pubitemid 32509594)
37. Taddei S, Bruno RM, Ghiadoni L. The correct administration of antihypertensive drugs according to the principles of clinical pharmacology. Am J Cardiovasc Drugs 2011;11:13-20
38. Myers MG. A dose-response study of perindopril in hypertension: effects of blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group. Can J Cardiol 1996;12:1191-6 (Pubitemid 26413308)
39. Morgan T, Anderson A. How important is 24-hour control of blood pressure? Drug Saf 1996;15:243-8 (Pubitemid 26358586)
40. Morgan T. Twenty four hour BP control-which is best, throught:peack ratios or ABPM? Br J Cardiol 1995;2(Suppl 1):S7-9
41. Julius S, Cohn JN, Neutel J, et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens (Greenwich) 2004;6:10-17
42. Poggi L, Renucci JF, Denolle T. Tratment of essential hypertension in general practice: an open-label study of 47 351 French hypertensive patients treated for one year with perindopril. Can J Cardiol 1994;10(Suppl D):21D-24D
43. Speirs C, Wagniart F, Poggi L. Perindopril post-marketing surveillance: a 12 month study in 14,351 hypertensive patients. Br J Clin Pharmacol 1998;46:63-70 (Pubitemid 28308426)
44. Ionescu DD; on behalf of the PREFER investigators. Antihypertensive efficacy of perindopril 5-10 mg in primary health care. Clin Drug Investig 2009;29:767-76
45. Tsoukas G, Tsoukas G, Anand S, Yang K; CONFIDENCE Investigators. Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. Am J Cardiovasc Drugs 2011;11(1):45-55
46. Rothwell Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905
47. Rothwell PM, Howard SC, Dolan E, et al. ASCOT-BPLA and MRC Trial Investigators. Effects of beta-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9:469-80
48. Williams B, Lacy PS, Thom SM, et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25
49. Asmar RG, London GM, O'Rourke ME, et al. on behalf of REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflection with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 2001;38:922-6 (Pubitemid 34258694)
50. de Luca N, Asmar RG, London GM, et al. REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004;22:1623-30 (Pubitemid 39037615)
51. Vlachopoulos C, Aznaouridis K, O'Rourke MF, et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010;31:1865-71
52. Ghiadoni L, Bruno RM, Stea F, et al. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep 2009;11:190-6
53. Laurent S. Evidence for benefits of perindopril in hypertension and its complications. Am J Hypertens 2005;18:155S-162S (Pubitemid 41206572)
54. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006;48:80-6 (Pubitemid 44313590)
55. Guerin AP, Blacher J, Pannier B, et al. Impact ofaortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-92 (Pubitemid 32183805)
56. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363-8 (Pubitemid 40165345)
57. Rizzoni D, Porteri E, Boari GE, et al. Prognostic significance of small-artery structure in hypertension. Circulation 2003;108:2230-5 (Pubitemid 37363040)
58. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003;41:1281-6 (Pubitemid 36706078)
59. Ghiadoni L, Magagna A, Kardasz I, et al. Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients. Am J Hypertens 2009;22:506-12
60. Thybo NK, Stephens N, Cooper A, et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995;25(4 Pt 1):474-81
61. Adler A, Stratton IM, Neil H, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: UKPDS 36. Prospective observational study. BMJ 2000;321:412-19 (Pubitemid 30609443)
62. Ghiadoni L. Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected]. Expert Opin Pharmacother 2010;11:1647-57. Erratum in: Expert Opin Pharmacother 2010;11;1963
63. de Galan BE, Perkovic V, Ninomiya T, et al.; ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-9
64. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8 (Pubitemid 44209181)
65. Brugts JJ, Ninomiya T, Boersma E, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009;30:1385-9
66. Mourad JJ, Bertrand M. Impact of antihypertensive treatment on mortality: a late - break analysis of recent clinical trials in hypertension [abstract]. J Hypertens 2010;28(e-Suppl A):e396
67. Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians Desk Reference. Am J Med 2010;123:1016-30
68. Clark LT. Safety profile of perindopril. Am J Cardiol 2001;88(7A):36i-40i (Pubitemid 32925101)
69. Brugts JJ, Isaacs A, de Maat MP, et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin- converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens 2011;29:509-19